Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Clinical trial NCT00130936 · TERMINATED
Trial details
- NCT number
- NCT00130936
- Sponsor
- AHS Cancer Control Alberta
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-10-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.